PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT 2.1 Preface 2.2 Preface 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE Market ecosystem Market characteristics Market segmentation analysis PART 04: MARKET SIZING Market definition Market sizing 2018 Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS Bargaining power of buyers Bargaining power of suppliers Threat of new entrants Threat of substitutes Threat of rivalry Market condition PART 06: MARKET SEGMENTATION BY TYPE Market segmentation by type Comparison by type Cancer vaccines - Market size and forecast 2018-2023 Infectious diseases vaccines - Market size and forecast 2018-2023 Other diseases vaccines - Market size and forecast 2018-2023 Neurological diseases vaccines - Market size and forecast 2018-2023 Autoimmune diseases vaccines - Market size and forecast 2018-2023 Market opportunity by type PART 07: CUSTOMER LANDSCAPE PART 08: GEOGRAPHIC LANDSCAPE Geographic segmentation Geographic comparison North America - Market size and forecast 2018-2023 Europe - Market size and forecast 2018-2023 Asia - Market size and forecast 2018-2023 ROW - Market size and forecast 2018-2023 Key leading countries Market opportunity PART 09: DECISION FRAMEWORK PART 10: DRIVERS AND CHALLENGES Market drivers Market challenges PART 11: MARKET TRENDS Market trends PART 12: VENDOR LANDSCAPE Overview Landscape disruption PART 13: VENDOR ANALYSIS Vendors covered Vendor classification Market positioning of vendors Aimmune Therapeutics, Inc. Immune Response BioPharma Inc. Inovio Pharmaceuticals Inc. Novartis AG Sanpower Group Co. Ltd. PART 14: APPENDIX Research methodology List of abbreviations Definition of market positioning of vendors PART 15: EXPLORE TECHNAVIO   Exhibit 01: Global vaccine market Exhibit 02: Segments of global vaccine market Exhibit 03: Market characteristics Exhibit 04: Market segments Exhibit 05: Market definition - Inclusions and exclusions checklist Exhibit 06: Market size 2018 Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 08: Global market: Year-over-year growth 2019-2023 (%) Exhibit 09: Five forces analysis 2018 Exhibit 10: Five forces analysis 2023 Exhibit 11: Bargaining power of buyers Exhibit 12: Bargaining power of suppliers Exhibit 13: Threat of new entrants Exhibit 14: Threat of substitutes Exhibit 15: Threat of rivalry Exhibit 16: Market condition - Five forces 2018 Exhibit 17: Type - Market share 2018-2023 (%) Exhibit 18: Comparison by type Exhibit 19: Cancer vaccines - Market size and forecast 2018-2023 ($ millions) Exhibit 20: Cancer vaccines - Year-over-year growth 2019-2023 (%) Exhibit 21: Infectious diseases vaccines - Market size and forecast 2018-2023 ($ millions) Exhibit 22: Infectious diseases vaccines - Year-over-year growth 2019-2023 (%) Exhibit 23: Vaccines under development for infectious diseases Exhibit 24: Other diseases vaccines - Market size and forecast 2018-2023 ($ millions) Exhibit 25: Other diseases vaccines - Year-over-year growth 2019-2023 (%) Exhibit 26: Vaccines under development for other diseases Exhibit 27: Neurological diseases vaccines - Market size and forecast 2018-2023 ($ millions) Exhibit 28: Neurological diseases vaccines - Year-over-year growth 2019-2023 (%) Exhibit 29: Vaccines under development for neurological diseases Exhibit 30: Autoimmune diseases vaccines - Market size and forecast 2018-2023 ($ millions) Exhibit 31: Autoimmune diseases vaccines - Year-over-year growth 2019-2023 (%) Exhibit 32: Vaccines under development for autoimmune diseases Exhibit 33: Market opportunity by type Exhibit 34: Customer landscape Exhibit 35: Market share by geography 2018-2023 (%) Exhibit 36: Geographic comparison Exhibit 37: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 38: North America - Year-over-year growth 2019-2023 (%) Exhibit 39: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 40: Europe - Year-over-year growth 2019-2023 (%) Exhibit 41: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 42: Asia - Year-over-year growth 2019-2023 (%) Exhibit 43: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 44: ROW - Year-over-year growth 2019-2023 (%) Exhibit 45: Key leading countries Exhibit 46: Market opportunity Exhibit 47: Vaccines under development Exhibit 48: Impact of drivers and challenges Exhibit 49: Vendor landscape Exhibit 50: Landscape disruption Exhibit 51: Vendors covered Exhibit 52: Vendor classification Exhibit 53: Market positioning of vendors Exhibit 54: Aimmune Therapeutics Inc. - Vendor overview Exhibit 55: Aimmune Therapeutics Inc. - Business segments Exhibit 56: Aimmune Therapeutics Inc. - Organizational developments Exhibit 57: Aimmune Therapeutics Inc. - Key offerings Exhibit 58: Immune Response BioPharma Inc. - Vendor overview Exhibit 59: Immune Response BioPharma Inc. - Key offerings Exhibit 60: Inovio Pharmaceuticals Inc. - Vendor overview Exhibit 61: Inovio Pharmaceuticals Inc. - Product segments Exhibit 62: Inovio Pharmaceuticals Inc. - Organizational developments Exhibit 63: Inovio Pharmaceuticals Inc. - Key offerings Exhibit 64: Novartis AG - Vendor overview Exhibit 65: Novartis AG - Business segments Exhibit 66: Novartis AG - Organizational developments Exhibit 67: Novartis AG - Geographic focus Exhibit 68: Novartis AG - Segment focus Exhibit 69: Novartis AG - Key offerings Exhibit 70: Sanpower Group Co. Ltd. - Vendor overview Exhibit 71: Sanpower Group Co. Ltd. - Key offerings Exhibit 72: Validation techniques employed for market sizing Exhibit 73: Definition of market positioning of vendors

Aimmune Therapeutics Inc. Immune Response BioPharma Inc. Inovio Pharmaceuticals Inc. Novartis AG Sanpower Group Co. Ltd.